Compare Ginkgo Bioworks Holdings Inc (DNA) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance

Ginkgo Bioworks (DNA) trades at $13.00, up 13.34% today, with a bullish technical signal from moving averages. The company shows strong gross margins of 68.04% but remains unprofitable with a -219.6% net margin. Recent news includes a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnership expansions, though revenue declined to $132M in 2026.

DNA presents high risk with significant losses and cash burn, but analyst sentiment is divided with equal buy/sell ratings. Investment appeal hinges on future profitability from recent partnerships and government contracts, while current financials and negative cash flow pose substantial downside risk.

Royal Caribbean (RCL) trades at $281.39, showing modest daily weakness but maintaining strong bullish momentum with analyst consensus pointing to significant upside. The company demonstrates robust fundamentals with revenue growth from $8.8B in 2022 to $17.9B in 2025, net income margin expanding to 23.54%, and positive cash flow generation. Recent developments include a $3B investment in Sandals Resorts and strong Q2 2026 earnings beat, while technical indicators show the stock trading near key resistance levels with overall bullish signals.

RCL presents compelling investment potential with 23% upside to consensus price target of $346.67, supported by strong earnings momentum and expanding profitability. However, risks include elevated debt levels, execution challenges from the Sandals acquisition, and sensitivity to fuel price volatility. The stock's current valuation at 17.38x P/E appears reasonable given the company's growth trajectory and industry-leading margins.